RSU vesting adds 2,954 Tarsus (TARS) shares to director’s holdings

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Tarsus Pharmaceuticals director Andrew D. Goldberg acquired 2,954 shares of common stock through the vesting and settlement of Restricted Stock Units (RSUs). The RSUs were granted on June 12, 2025 for his service as a non-employee director and vested in full one year later.

Following this compensation-related share issuance, Goldberg directly holds 19,654 shares of Tarsus common stock. The filing shows no open-market purchases or sales, only the conversion of previously granted RSUs into common shares.

Insider Trade Summary

2,954 shares exercised/converted

Mixed 2 txns

Insider Goldberg Andrew D.

Role null

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	2,954	$0.00	--
Exercise	Common Stock	2,954	$0.00	--

Holdings After Transaction: Restricted Stock Units — 0 shares (Direct, null); Common Stock — 19,654 shares (Direct, null)

Footnotes (1)

The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. Each RSU represents a contingent right to receive one share of the Company's common stock. RSUs granted on June 12, 2025, in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

Key Figures

RSUs converted: 2,954 shares Shares held after: 19,654 shares RSU grant date: June 12, 2025 +1 more

4 metrics

RSUs converted 2,954 shares RSUs settled into common stock on June 12, 2026

Shares held after 19,654 shares Direct Tarsus common stock holdings following RSU vesting

RSU grant date June 12, 2025 Grant in connection with non-employee director service

Exercise/Conversion price $0.00 per share RSUs settled into common stock without cash exercise price

Key Terms

Restricted Stock Units, derivative exercise/conversion, non-employee director

3 terms

Restricted Stock Units financial

"The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs")."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

derivative exercise/conversion financial

"transaction_action: "derivative exercise/conversion" for the RSU settlement."

non-employee director financial

"RSUs granted on June 12, 2025, in connection with the Reporting Person's service as a non-employee director."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/16/2026 - 04:05 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Goldberg Andrew D.

(Last)

(First)

(Middle)

C/O TARSUS PHARMACEUTICALS, INC.

15440 LAGUNA CANYON ROAD, SUITE 160

(Street)

IRVINE

CALIFORNIA

92618

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tarsus Pharmaceuticals, Inc. [ TARS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/12/2026		M⁽¹⁾		2,954	A	⁽¹⁾	19,654	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽²⁾	06/12/2026		M			2,954	⁽³⁾	⁽³⁾	Common Stock	2,954	$0	0	D

Explanation of Responses:

1. The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.

2. Each RSU represents a contingent right to receive one share of the Company's common stock.

3. RSUs granted on June 12, 2025, in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

Remarks:

	/s/ Jeffrey Farrow, Attorney-in-Fact	06/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Tarsus (TARS) director Andrew Goldberg report in this Form 4?

Andrew D. Goldberg reported acquiring 2,954 Tarsus common shares through vesting and settlement of Restricted Stock Units. This is a compensation-related conversion of RSUs into stock, with no open-market buying or selling disclosed in the filing.

Did Andrew Goldberg buy or sell Tarsus (TARS) shares on the market?

No market purchases or sales were reported. The Form 4 shows only an exercise/conversion of 2,954 RSUs into Tarsus common stock, a routine compensation event rather than an open-market trading decision involving cash transactions.

How many Tarsus (TARS) shares does Andrew Goldberg hold after this RSU vesting?

After the RSU settlement, Andrew D. Goldberg directly holds 19,654 shares of Tarsus common stock. This total reflects his position following the issuance of 2,954 shares tied to vested Restricted Stock Units granted for board service.

What are the key details of the RSUs reported by Tarsus (TARS) director Goldberg?

The RSUs were granted on June 12, 2025 in connection with Goldberg’s service as a non-employee director. Each RSU represented a right to receive one Tarsus common share and vested in full on the one-year anniversary, triggering issuance of 2,954 shares.

Does this Tarsus (TARS) Form 4 indicate any remaining RSUs or derivatives for Andrew Goldberg?

The filing shows 2,954 RSUs converted into common stock, leaving zero RSUs in that specific award after settlement. The derivative summary indicates no remaining derivative positions visible in this filing for Goldberg following the reported RSU vesting event.